Media Centre
The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public.
To access, please confirm that you are an accredited member of the press.
I hereby confirm that I am an accredited member of the press
Press Releases
27, May, 2022
Janssen Responds to NICE Assessment for SPRAVATO®▼ (Esketamine) Nasal Spray for Treatment-Resistant Major Depressive Disorder
01, February, 2022
BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) Authorised in Great Britain for the Maintenance Treatment of Schizophrenia in Adults
08, September, 2021
NICE backs Janssen’s Erleada®▼ (apalutamide) for Hormone-Sensitive Metastatic and Hormone-Relapsed Non-Metastatic Prostate Cancer
Quick Links
FOLLOW US
Janssen UK
@JanssenUK

-
“To better understand our role and application of technology, we first must ask the question: how will it improve p… https://t.co/zXTs5gUwWD
3 weeks 20 hours ago